US · ANL · BIOTECHNOLOGY
Adlai Nortye Ltd. (ANL) intrinsic value and stock valuation
$8.55as of 2026-11-21 · Mkt cap 693.76M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Adlai Nortye Ltd. DCF and intrinsic value
InvestorsCraft values ANL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ANL’s statements →
Adlai Nortye Ltd. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Apollomics, Inc. (APLM) $15.54
- OSR Holdings, Inc. (OSRH) $0.12
- Lipocine Inc. (LPCN) $1.48
- BioLineRx Ltd. (BLRX) $0.96
- Ainos, Inc. (AIMD) $1.18
- SeaStar Medical Holding Corporation (ICU) $0.94
- GeoVax Labs, Inc. (GOVX) $1.81
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5M | $0.00 | $0.00 | $0.00 | $45.7M |
| Operating income | -$-35.7M | -$-52.93M | -$-72.55M | -$-67.27M | -$-8.65M |
| Net income | -$-35.53M | -$-51.87M | -$-109.23M | -$-58.79M | -$-56.68M |
| EPSd | -$-3.33M | -$-4.87M | -$-16.06M | -$-6.93M | -$-6.68M |
| Operating cash flow | -$-33.54M | -$-51.82M | -$-56.65M | -$-43.22M | -$-3.03M |
| Capital expenditure | -$-190K | -$-170K | -$-200K | -$-1.27M | -$-1.12M |
| Free cash flow | -$-33.73M | -$-51.99M | -$-56.85M | -$-44.49M | -$-4.15M |
| Total assets | $34.4M | $71.3M | $130.2M | $72.6M | $131.7M |
| Total debt | $26.4M | $27.2M | $31.6M | $6.54M | $13.4M |
| Net debt | $2.59M | -$-33.68M | -$-59.94M | -$-36.21M | -$-50.79M |
| Total equity | -$-8.32M | $25.5M | $75.1M | -$-241.29M | -$-185.43M |
| Cash and short-term investments | $23.8M | $60.9M | $98.5M | $64.1M | $117.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5M | $0.00 | $0.00 | $0.00 | $45.7M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $5M | $0.00 | $0.00 | $0.00 | $45.7M |
| Research and development expenses | $32.8M | $44.9M | $58.2M | $54.5M | $42.1M |
| Selling, general and administrative expenses | $7.79M | $9.44M | $14.8M | $12.4M | $12.5M |
| Other expenses | $80K | -$-1.43M | -$-420K | $350K | -$-180K |
| Operating expenses | $40.7M | $52.9M | $72.6M | $67.3M | $54.4M |
| Cost and expenses | $40.7M | $52.9M | $72.6M | $67.3M | $54.4M |
| Interest income | $0.00 | $0.00 | $60K | $550K | $30K |
| Interest expense | $1.49M | $1.94M | $790K | $430K | $1.34M |
| Depreciation and amortization | $1.41M | $1.87M | $2.22M | $2.04M | $1.83M |
| Ebitda | -$-32.63M | -$-48.05M | -$-106.22M | -$-56.32M | -$-53.51M |
| Operating income | -$-35.7M | -$-52.93M | -$-72.55M | -$-67.27M | -$-8.65M |
| Total other income/expenses, net | $170K | $1.06M | -$-36.68M | $8.48M | -$-48.03M |
| Income before tax | -$-35.53M | -$-51.87M | -$-109.23M | -$-58.79M | -$-56.68M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-35.53M | -$-51.87M | -$-109.23M | -$-58.79M | -$-56.68M |
| Weighted average shares outstanding | $10.7M | $10.6M | $6.8M | $8.48M | $8.48M |
| Weighted average diluted shares outstanding | $10.7M | $10.6M | $6.8M | $8.48M | $8.48M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $23.8M | $60.9M | $98.5M | $64.1M | $117.9M |
| Net receivables | $1.39M | $1.17M | $360K | $350K | $1.93M |
| Inventory | $0.00 | $0.00 | $0.00 | -$0.00 | $0.00 |
| Total current assets | $26.9M | $64.1M | $101.2M | $66.3M | $124.5M |
| Property, plant and equipment, net | $3.02M | $2.71M | $3.8M | $5.88M | $6.59M |
| Goodwill and intangible assets | $20K | $40K | $60K | $90K | $100K |
| Long-term investments | $4.25M | $4.16M | $24.9M | $0.00 | $0.00 |
| Total non-current assets | $7.54M | $7.21M | $29M | $6.29M | $7.14M |
| Total assets | $34.4M | $71.3M | $130.2M | $72.6M | $131.7M |
| Accounts payable | $12.6M | $10.2M | $14.4M | $13.1M | $2.98M |
| Short-term debt | $25.3M | $26.8M | $31.1M | $5.31M | $11.3M |
| Deferred revenue | $0.00 | $5M | $0.00 | $3.88M | $0.00 |
| Total current liabilities | $41.6M | $45.4M | $49.7M | $312.7M | $17.5M |
| Long-term debt | $1.13M | $420K | $470K | $1.24M | $2.05M |
| Deferred revenue, non-current | $0.00 | $0.00 | $5M | $0.00 | $0.00 |
| Total non-current liabilities | $1.13M | $420K | $5.47M | $1.24M | $299.6M |
| Capital lease obligations | $1.13M | $900K | $1.19M | $2.24M | $2.89M |
| Total liabilities | $42.8M | $45.8M | $55.1M | $313.9M | $317.1M |
| Common stock | $10K | $10K | $10K | $0.00 | $0.00 |
| Retained earnings | -$-464.85M | -$-429.32M | -$-373.09M | -$-268.22M | -$-209.43M |
| Accumulated other comprehensive income (loss) | $17.3M | -$-4.54M | -$-4.24M | $9.53M | -$-1M |
| Total equity | -$-8.32M | $25.5M | $75.1M | -$-241.29M | -$-185.43M |
| Total investments | $4.25M | $4.16M | $31.9M | $21.3M | $53.8M |
| Total debt | $26.4M | $27.2M | $31.6M | $6.54M | $13.4M |
| Net debt | $2.59M | -$-33.68M | -$-59.94M | -$-36.21M | -$-50.79M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-35.62M | -$-51.87M | -$-104.87M | -$-58.79M | -$-56.68M |
| Depreciation and amortization | $1.42M | $1.87M | $2.22M | $2.04M | $1.83M |
| Stock-based compensation | $0.00 | $2.45M | $4.33M | $6.08M | $3.39M |
| Change in working capital | -$-2.29M | -$-5.54M | $6.12M | $15.3M | $250K |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $2.5M | -$-4.2M | $1.25M | $10.1M | $600K |
| Net cash provided by operating activities | -$-33.54M | -$-51.82M | -$-56.65M | -$-43.22M | -$-3.03M |
| Investments in property, plant and equipment | -$-190K | -$-170K | -$-200K | -$-1.27M | -$-1.12M |
| Acquisitions, net | $0.00 | -$-4.21M | $0.00 | -$0.00 | -$-100K |
| Net cash used for investing activities | -$-15.62M | $28.1M | -$-10.95M | $28.4M | -$-54.86M |
| Common stock issued | $0.00 | $150K | $91.8M | $0.00 | $97.4M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-3.82M | -$-6.58M | $116.2M | -$-6.78M | $97.2M |
| Net change in cash | -$-37.12M | -$-30.59M | $48.7M | -$-21.37M | $39.9M |
| Cash at end of period | $23.8M | $60.9M | $91.5M | $42.8M | $64.1M |
| Operating cash flow | -$-33.54M | -$-51.82M | -$-56.65M | -$-43.22M | -$-3.03M |
| Capital expenditure | -$-190K | -$-170K | -$-200K | -$-1.27M | -$-1.12M |
| Free cash flow | -$-33.73M | -$-51.99M | -$-56.85M | -$-44.49M | -$-4.15M |
Line items
Line items
Line items
About Adlai Nortye Ltd.
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
- CEO
- Yang Lu
- Employees
- 109
- Beta
- 1.16
Explore
Frequently asked questions
What is the intrinsic value of Adlai Nortye Ltd. (ANL)?
InvestorsCraft does not currently publish an intrinsic value for ANL. How the IC value is calculated.
Is ANL undervalued?
InvestorsCraft does not publish an undervaluation signal for ANL at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.